Comparison tool

Copper Peptide AHK-Cu vs Argireline side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

Copper Peptide AHK-CuArgireline

Share this peptide comparison

Property	Copper Peptide AHK-Cu	Argireline
Category	Skin & Hair	Skin & Hair
Also known as	Tripeptide-3, Ala-His-Lys Copper	Acetyl Hexapeptide-3, Acetyl Hexapeptide-8
FDA approved	No	No
Clinical status	Cosmetic use - Hair care products Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	Cosmetic use - widely available Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Hair growth, scalp health, hair thickness	Wrinkle reduction, forehead lines, eye area anti-aging
How it works	AHK-Cu is described as a copper-bound alanine-histidine-lysine tripeptide. In the supplied material, its proposed hair-related mechanism is centered on copper signaling in follicle-associated biology, especially dermal papilla cells. Reported cell and isolated-follicle findings include increased dermal papilla cell proliferation, reduced apoptosis markers, and a shift in survival-related proteins with higher Bcl-2 and lower Bax. The source explicitly limits these mechanistic observations to cells and isolated follicles rather than proven human scalp outcomes.	Argireline is described as an acetyl hexapeptide-8 fragment connected to SNAP-25, a protein involved in the SNARE machinery for acetylcholine release. The source reports that early laboratory work found neurotransmitter-release inhibition in cell systems. A key limitation is topical delivery: the supplied review summary notes disagreement about skin penetration and states that in vivo demonstration of the marketed muscle-inhibition mechanism was not shown.
Typical dosing	Limited community data available · See research protocols	Limited community data available · See research protocols
Research dosing	Topical solutions and serums · 3-6 months for visible results · Topical (scalp serums, solutions)	5-10% concentration in formulations · Ongoing use for maintained effects · Topical (serums, creams)
Typical duration	3-6 months for visible results	Ongoing use for maintained effects
Administration	Topical (scalp serums, solutions)	Topical (serums, creams)
Timing	Morning or as directed With or without food	Morning and evening (topical) With or without food
Evidence level	Research	Research
Possible side effects	Generally well-tolerated Skin irritation Allergic reactions (Rare) +2 more Risk of copper toxicity if combined with copper sources (Source flags this as a caution when other copper sources are also used.) Contraindicated with Wilson's disease (Source lists Wilson's disease as a contraindication.)	Generally very safe (Reported in source as a general safety characterization; not an FDA safety determination.) Mild skin irritation (Rare in the supplied source.) Redness or tingling (Rare in the supplied source.) +1 more Fewer side effects than botulinum toxin (Comparative statement from source; does not establish equivalence or treatment substitution.)
Research summary	The main research signal supplied is a 2007 Archives of Pharmacal Research study by Pyo and colleagues. The source states that AHK-Cu was tested outside the body using human hair follicles and dermal papilla cells. At low concentrations, it reportedly increased isolated follicle length and dermal papilla cell proliferation while lowering apoptosis-related markers. The source also notes a narrow dose-response pattern in which higher concentrations no longer showed the same activity. The important limitation is that the source does not identify randomized controlled human trials showing that topical AHK-Cu regrows or thickens scalp hair in people.	The source summary cites a 2002 Blanes-Mira study using a 10% peptide oil-in-water emulsion and reporting a 30% wrinkle-depth reduction, alongside cell-assay support for SNARE interference. It also describes a small double-blind split-face study in 19 women where four weeks of Argireline serum did not significantly outperform placebo by VISIA imaging and was not considered a botulinum toxin substitute. A 2025 review is reported to have found inconsistent penetration estimates, about 30% stratum-corneum passage in one study versus about 0.2% in another, and no in vivo proof of the proposed muscle-inhibition mechanism. Overall, the supplied evidence frames Argireline as a plausible cosmetic peptide with limited and mixed human data, while noting no serious adverse effects reported.
References	PubMed Springer +1 more Semantic Scholar	PubMed Wiley Online Library +3 more PubMed Central PubMed Central WikipediaAcetyl hexapeptide-8
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Copper Peptide AHK-Cu

Argireline

Category

Skin & Hair

Also known as

Tripeptide-3, Ala-His-Lys Copper

Acetyl Hexapeptide-3, Acetyl Hexapeptide-8

FDA approved

Clinical status

Cosmetic use - Hair care products

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

Cosmetic use - widely available

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Hair growth, scalp health, hair thickness

Wrinkle reduction, forehead lines, eye area anti-aging

How it works

AHK-Cu is described as a copper-bound alanine-histidine-lysine tripeptide. In the supplied material, its proposed hair-related mechanism is centered on copper signaling in follicle-associated biology, especially dermal papilla cells. Reported cell and isolated-follicle findings include increased dermal papilla cell proliferation, reduced apoptosis markers, and a shift in survival-related proteins with higher Bcl-2 and lower Bax. The source explicitly limits these mechanistic observations to cells and isolated follicles rather than proven human scalp outcomes.

Argireline is described as an acetyl hexapeptide-8 fragment connected to SNAP-25, a protein involved in the SNARE machinery for acetylcholine release. The source reports that early laboratory work found neurotransmitter-release inhibition in cell systems. A key limitation is topical delivery: the supplied review summary notes disagreement about skin penetration and states that in vivo demonstration of the marketed muscle-inhibition mechanism was not shown.

Typical dosing

Limited community data available · See research protocols

Research dosing

Topical solutions and serums · 3-6 months for visible results · Topical (scalp serums, solutions)

5-10% concentration in formulations · Ongoing use for maintained effects · Topical (serums, creams)

Typical duration

3-6 months for visible results

Ongoing use for maintained effects

Administration

Topical (scalp serums, solutions)

Topical (serums, creams)

Timing

Morning or as directed

With or without food

Morning and evening (topical)

With or without food

Evidence level

Research

Possible side effects

Generally well-tolerated
Skin irritation
Allergic reactions (Rare)

+2 more

Risk of copper toxicity if combined with copper sources (Source flags this as a caution when other copper sources are also used.)
Contraindicated with Wilson's disease (Source lists Wilson's disease as a contraindication.)

Generally very safe (Reported in source as a general safety characterization; not an FDA safety determination.)
Mild skin irritation (Rare in the supplied source.)
Redness or tingling (Rare in the supplied source.)

+1 more

Fewer side effects than botulinum toxin (Comparative statement from source; does not establish equivalence or treatment substitution.)

Research summary

The main research signal supplied is a 2007 Archives of Pharmacal Research study by Pyo and colleagues. The source states that AHK-Cu was tested outside the body using human hair follicles and dermal papilla cells. At low concentrations, it reportedly increased isolated follicle length and dermal papilla cell proliferation while lowering apoptosis-related markers. The source also notes a narrow dose-response pattern in which higher concentrations no longer showed the same activity. The important limitation is that the source does not identify randomized controlled human trials showing that topical AHK-Cu regrows or thickens scalp hair in people.

The source summary cites a 2002 Blanes-Mira study using a 10% peptide oil-in-water emulsion and reporting a 30% wrinkle-depth reduction, alongside cell-assay support for SNARE interference. It also describes a small double-blind split-face study in 19 women where four weeks of Argireline serum did not significantly outperform placebo by VISIA imaging and was not considered a botulinum toxin substitute. A 2025 review is reported to have found inconsistent penetration estimates, about 30% stratum-corneum passage in one study versus about 0.2% in another, and no in vivo proof of the proposed muscle-inhibition mechanism. Overall, the supplied evidence frames Argireline as a plausible cosmetic peptide with limited and mixed human data, while noting no serious adverse effects reported.

References

PubMed Springer

+1 more

Semantic Scholar

PubMed Wiley Online Library

+3 more

PubMed Central PubMed Central WikipediaAcetyl hexapeptide-8

Full profile

View Details